‹ ›
MYP_062242
← PREVIOUS NEXT → BACK
Basic Information
ENF (T-20)
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Anti-Pneumovirus ▸ Anti-RSV
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition ▸ Entry inhibitor
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Standard
36 amino acids
C202H298N50O64
Standard
Sequence
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
Physicochemical Analysis
4450.82 Da
4.30
-5.14
-5.41
-0.1427
-0.88
0.46
-0.05
62.65
89.44
0.1389
17990.00
17990.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1894.02
-14.96
63.0
60.0
150.0
316.0
9.0
42.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0010709 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
CEM4
0.05 μg/mL
IC50
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0024894 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 HXB2 | TZM-bl cells
0.024633±0.002467 μM
IC50
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | Chong H, Zhu Y, Yu D, He Y. | J Virol. 2018 Sep 26;92(20):e01088-18. | DOI:10.1128/JVI.01088-18 | PMID:30089693 PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0025812 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-SIV Fusion inhibition
SIV (239,PBJ) | TZM-bl cells
0.4908-0.64849 μM
IC50
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | Chong H, Zhu Y, Yu D, He Y. | J Virol. 2018 Sep 26;92(20):e01088-18. | DOI:10.1128/JVI.01088-18 | PMID:30089693 PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0028804 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral
098-T651 virus
47.822 μg/mL
IC50
Male cynomolgus monkey blood plasma (Intravenous), in vivo; 31680 s
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0030627 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 pseudoviruss (7 pseudoviruss) | MT-2 cells
0.0071-0.091 μM
IC50
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperCreating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. | Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. | J Virol. 2016 Dec 16;91(1):e01445-16. | DOI:10.1128/JVI.01445-16 | PMID:27795416 PMID27795416 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27795416/
1 2 3 ... 14 NEXT LAST
Showing 5 records on this page · Page 1 of 14